Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-304 in first-line metastatic non-small cell lung cancer
2019-003372-39Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing INCMGA00012 plus platinum-based chemotherapy with Placebo plus platinum-based chemotherapy (2 arms). Primary endpoints: overall survival and objective response rate. Started Jun 2020; status: terminated.
02
Drugs
retifanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003372-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003372-39.